MET and neoplasm: The novel targeted tumor suppressor (PYR26) was designed and synthesized based on the structural similarities and differences between the crystalline complexes of EGFR and c-Met and their respective ligands, and this study demonstrated the significant proliferation inhibitory effect of PYR26 on HepG2 cells at the cellular level after 24h by CCK-8 and microscopic observation.